AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33814529 — intervention group
Group type: COMPARATOR
Intervention: Change less than the median %ΔEPA/AA ratio (Group 1)
Number of subjects: 965
Study 33503851 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain Training with Sulforaphane (BT-S)
Number of subjects: 144
Study 33503851 — intervention group
Group type: COMPARATOR
Intervention: Brain Training with Placebo (BT-P)
Number of subjects: 144
Study 33503851 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Control Game with Sulforaphane (AT-S)
Number of subjects: 144
Study 33503851 — intervention group
Group type: COMPARATOR
Intervention: Active Control Game with Placebo (AT-P)
Number of subjects: 144
Study 32114612 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized music (PM)
Number of subjects: 52
Study 32114612 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-tempo music (STM)
Number of subjects: 52
Study 32114612 — intervention group
Group type: COMPARATOR
Intervention: Attention control (AC)
Number of subjects: 52
Study 34794108 — intervention group
Group type: EXPERIMENTAL
Intervention: VVZ‐149 (n = 40)
Number of subjects: 60
Study 34794108 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 20)
Number of subjects: 60
Study 33481017 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-omics analysis using transcriptome and/or DNA methylation data from various projects.
Number of subjects: 0
Study 33481017 — intervention group
Group type: EXPERIMENTAL
Intervention: Summary-data-based Mendelian randomization approach (SMR).
Number of subjects: 0
Study 33481017 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonferroni-corrected PSMR < 0.05.
Number of subjects: 0
Study 33481017 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro assays for genes DIP2B and SFMBT1.
Number of subjects: 0
Study 32353906 — intervention group
Group type: EXPERIMENTAL
Intervention: 11 for Health in Denmark intervention (2×45 min/week of football drills and health education for 11 weeks)
Number of subjects: 3061
Study 32353906 — intervention group
Group type: EXPERIMENTAL
Intervention: 11 for Health in Denmark intervention
Number of subjects: 3061
Study 32353906 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 3061
Study 35346270 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-guided radiotherapy (MRgRT)
Number of subjects: 82
Study 35346270 — intervention group
Group type: COMPARATOR
Intervention: ITV-based stereotactic body radiotherapy (SBRT)
Number of subjects: 82
Study 35346270 — intervention group
Group type: EXPERIMENTAL
Intervention: MRgRT
Number of subjects: 82
Study 35346270 — intervention group
Group type: EXPERIMENTAL
Intervention: Potential prognostic biomarkers
Number of subjects: 82
Study 33120362 — intervention group
Group type: EXPERIMENTAL
Intervention: Flywheel Inertial Leg Curl (FLC)
Number of subjects: 15
Study 33120362 — intervention group
Group type: COMPARATOR
Intervention: Nordic Hamstring Exercise (NHE)
Number of subjects: 15
Study 32098609 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 305
Study 32098609 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 305
Study 35989210 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone intervention
Number of subjects: 248
Study 34631986 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom Management Intervention (SMI) with tailored weekly group sessions and mobile health application
Number of subjects: 61
Study 34631986 — intervention group
Group type: COMPARATOR
Intervention: Control group received routine follow-ups and downloaded the Symptom Management (SM) app
Number of subjects: 61
Study 35860161 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided Quadratus Lumborum (QL) block
Number of subjects: 136
Study 35860161 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided Transversus Abdominis Plane (TAP) block
Number of subjects: 136
Study 32006994 — intervention group
Group type: EXPERIMENTAL
Intervention: Array Pairing Method (APM)
Number of subjects: 0
Study 32006994 — intervention group
Group type: EXPERIMENTAL
Intervention: Single and dual speaker experiment using APM
Number of subjects: 0
Study 37052334 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (10 mg orally, three times per day)
Number of subjects: 96
Study 37052334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 37052334 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 96
Study 33206270 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin with antioxidants therapy for 8 weeks
Number of subjects: 90
Study 33206270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 2015754071 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate topical adhesive
Number of subjects: 14
Study 2015754071 — intervention group
Group type: COMPARATOR
Intervention: Fast absorbing gut suture
Number of subjects: 14
Study 35954802 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental condition with accommodation strategies integrated into the HIV prevention session
Number of subjects: 20
Study 35954802 — intervention group
Group type: COMPARATOR
Intervention: Standard condition (control)
Number of subjects: 20
Study 32236762 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure interview (60-min duration)
Number of subjects: 134
Study 32236762 — intervention group
Group type: COMPARATOR
Intervention: Control (waitlist)
Number of subjects: 134
Study 32769505 — intervention group
Group type: EXPERIMENTAL
Intervention: Active nerve block with 20 ml of 0.375% levobupivacaine and clonidine 0.5 μg/kg
Number of subjects: 44
Study 32769505 — intervention group
Group type: COMPARATOR
Intervention: Simulated (sham) block only
Number of subjects: 44
Study 32769505 — intervention group
Group type: EXPERIMENTAL
Intervention: Active nerve block
Number of subjects: 44
Study 32769505 — intervention group
Group type: COMPARATOR
Intervention: Simulated (sham) block
Number of subjects: 44
Study 35089370 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical model using AdaBoost
Number of subjects: 101
Study 35089370 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical model using LDA
Number of subjects: 101
Study 35089370 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical model using LR
Number of subjects: 101
Study 35089370 — intervention group
Group type: EXPERIMENTAL
Intervention: Image model using AdaBoost
Number of subjects: 101
Study 35089370 — intervention group
Group type: EXPERIMENTAL
Intervention: Image model using LDA
Number of subjects: 101
Study 35089370 — intervention group
Group type: EXPERIMENTAL
Intervention: Image model using LR
Number of subjects: 101
Study 35089370 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined model using AdaBoost
Number of subjects: 101
Study 35089370 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined model using LDA
Number of subjects: 101
Study 35089370 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined model using LR
Number of subjects: 101
Study 34034786 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation (100,000 UI once a month for 6 months)
Number of subjects: 54
Study 34034786 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 54
Study 34626029 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-hour psychosocial support intervention delivered by volunteers
Number of subjects: 48
Study 34626029 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (Control Group)
Number of subjects: 48
Study 33008934 — intervention group
Group type: EXPERIMENTAL
Intervention: Lebrikizumab 250 mg subcutaneously every 4 weeks
Number of subjects: 505
Study 33008934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 505
Study 33008934 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Lebrikizumab with pirfenidone)
Number of subjects: 505
Study 32111310 — intervention group
Group type: EXPERIMENTAL
Intervention: Flattening on floor (FF) housing system
Number of subjects: 168
Study 32111310 — intervention group
Group type: COMPARATOR
Intervention: Conventional cage (CC) housing system
Number of subjects: 168
Study 32111310 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction of housing system and age
Number of subjects: 168
Study 32111310 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of hens
Number of subjects: 168
Study 32111310 — intervention group
Group type: EXPERIMENTAL
Intervention: Both housing systems
Number of subjects: 168
Study 34983646 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for abnormal transcranial Doppler (TCD) velocity and initiation of hydroxyurea as standard of care
Number of subjects: 0
Study 34983646 — intervention group
Group type: EXPERIMENTAL
Intervention: Efficacy trial for primary prevention of stroke
Number of subjects: 0
Study 34461211 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational analyses of existing databases
Number of subjects: 0
Study 34461211 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis of multiple studies
Number of subjects: 0
Study 34461211 — intervention group
Group type: EXPERIMENTAL
Intervention: Causal analysis
Number of subjects: 0
Study 33233227 — intervention group
Group type: EXPERIMENTAL
Intervention: Yacon syrup (40 g)
Number of subjects: 40
Study 33233227 — intervention group
Group type: COMPARATOR
Intervention: Placebo (40 g)
Number of subjects: 40
Study 36375976 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic hamstring exercise (NHE) program
Number of subjects: 0
Study 36375976 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular football training only)
Number of subjects: 0
Study 33639349 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved pellet quality feed
Number of subjects: 816
Study 33639349 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% biochar litter treatment
Number of subjects: 816
Study 33040103 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallbladder removal with retrieval bag
Number of subjects: 254
Study 33040103 — intervention group
Group type: COMPARATOR
Intervention: Gallbladder removal without retrieval bag
Number of subjects: 254
Study 33419452 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic partial pancreatoduodenectomy (RPD)
Number of subjects: 80
Study 33419452 — intervention group
Group type: COMPARATOR
Intervention: Open partial pancreatoduodenectomy (OPD)
Number of subjects: 80
Study 32763149 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular setback surgery (displacement greater than or equal to 5 mm)
Number of subjects: 30
Study 32763149 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular setback surgery (displacement less than 5 mm)
Number of subjects: 30
Study 35014593 — intervention group
Group type: EXPERIMENTAL
Intervention: Stiff shoe version
Number of subjects: 41
Study 35014593 — intervention group
Group type: COMPARATOR
Intervention: Soft shoe version
Number of subjects: 41
Study 34534883 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically determined ACR (urine albumin to creatinine ratio)
Number of subjects: 0
Study 34534883 — intervention group
Group type: COMPARATOR
Intervention: Genetically determined SUA (serum uric acid)
Number of subjects: 0
Study 34534883 — intervention group
Group type: COMPARATOR
Intervention: Genetically determined eGFRcre (estimated glomerular filtration rate based on serum creatinine)
Number of subjects: 0
Study 34534883 — intervention group
Group type: COMPARATOR
Intervention: Genetically determined eGFRcys (estimated glomerular filtration rate based on serum cystatin C)
Number of subjects: 0
Study 34534883 — intervention group
Group type: COMPARATOR
Intervention: Unweighted polygenic score for ACR
Number of subjects: 0
Study 34645853 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow deep breathing
Number of subjects: 15
Study 34645853 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 15
Study 32753522 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel Floss Holder (NFH)
Number of subjects: 142
Study 32753522 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel Floss Holder plus Text Messages (NFH+TM)
Number of subjects: 142
Study 32753522 — intervention group
Group type: COMPARATOR
Intervention: Finger Floss (FF)
Number of subjects: 142
Study 35142425 — intervention group
Group type: EXPERIMENTAL
Intervention: Teleconsultation
Number of subjects: 20
Study 35142425 — intervention group
Group type: COMPARATOR
Intervention: Phone consultation
Number of subjects: 20
Study 34706556 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI5884 (50, 100, 200, 350, or 500 mg SC)
Number of subjects: 132
Study 34706556 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI5884 (500 mg SC)
Number of subjects: 132
Study 34706556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 33683939 — intervention group
Group type: EXPERIMENTAL
Intervention: apalutamide, abiraterone acetate, prednisone and leuprolide (AAPL)
Number of subjects: 118
Study 33683939 — intervention group
Group type: COMPARATOR
Intervention: abiraterone, prednisone, leuprolide (APL)
Number of subjects: 118
Study 33683939 — intervention group
Group type: EXPERIMENTAL
Intervention: AAPL and APL (combined)
Number of subjects: 118
Study 32615798 — intervention group
Group type: EXPERIMENTAL
Intervention: Major amputation in patients with CLI at baseline
Number of subjects: 0
Study 32615798 — intervention group
Group type: EXPERIMENTAL
Intervention: Major amputation in patients without CLI at baseline
Number of subjects: 0
Study 32615798 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall major amputation in PAD patients
Number of subjects: 0
Study 32615798 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-day mortality rate after major amputation
Number of subjects: 0
Study 32615798 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual mortality rate following major amputation in CLI at baseline
Number of subjects: 0
Study 32615798 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual mortality rate following major amputation in no CLI at baseline
Number of subjects: 0
Study 35537372 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 29
Study 35537372 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengths training
Number of subjects: 29
Study 35537372 — intervention group
Group type: COMPARATOR
Intervention: Active control condition
Number of subjects: 29
Study 35537372 — intervention group
Group type: COMPARATOR
Intervention: Endurance training and Active control condition
Number of subjects: 29
Study 35537372 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise interventions (Endurance and Strengths)
Number of subjects: 29
Study 34711976 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 324
Study 34711976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 324
Study 33200954 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-cut and scalloped shaft work boot
Number of subjects: 0
Study 33200954 — intervention group
Group type: COMPARATOR
Intervention: Higher-cut straight shaft work boot
Number of subjects: 0
Study 32616158 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use at baseline
Number of subjects: 18096
Study 35681264 — intervention group
Group type: COMPARATOR
Intervention: Single immune checkpoint inhibitor (ICI)
Number of subjects: 4665
Study 35681264 — intervention group
Group type: COMPARATOR
Intervention: Single ICI plus chemotherapy
Number of subjects: 4665
Study 35681264 — intervention group
Group type: COMPARATOR
Intervention: Doublet ICIs
Number of subjects: 4665
Study 35681264 — intervention group
Group type: COMPARATOR
Intervention: Single ICI plus radiotherapy
Number of subjects: 4665
Study 34155332 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg/day of baclofen
Number of subjects: 120
Study 34155332 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/day of baclofen
Number of subjects: 120
Study 34155332 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 120
Study 32676976 — intervention group
Group type: EXPERIMENTAL
Intervention: Keguan-1 19.4 g twice daily plus control therapy (alpha interferon inhalation, 50 µg twice daily; and lopinavir/ritonavir, 400 and 100 mg twice daily)
Number of subjects: 48
Study 32676976 — intervention group
Group type: COMPARATOR
Intervention: Control therapy (alpha interferon inhalation, 50 µg twice daily; and lopinavir/ritonavir, 400 and 100 mg twice daily)
Number of subjects: 48
Study 35367661 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesor per 10 beats per min increase
Number of subjects: 6201
Study 35367661 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplitude per 5 bpm increase
Number of subjects: 6201
Study 35367661 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak time reached between 12:00-18:00
Number of subjects: 6201
Study 35367661 — intervention group
Group type: EXPERIMENTAL
Intervention: Combining APACHE IV score and circadian rhythm variables
Number of subjects: 6201
Study 33757646 — intervention group
Group type: EXPERIMENTAL
Intervention: Renin–angiotensin–aldosterone system blockers
Number of subjects: 0
Study 35660270 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant massage applied for 10 minutes before phototherapy
Number of subjects: 61
Study 35660270 — intervention group
Group type: COMPARATOR
Intervention: Control group (no massage)
Number of subjects: 61
Study 35660270 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant massage
Number of subjects: 61
Study 34175006 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-pandemic mental health assessments (baseline and 8-month follow-ups)
Number of subjects: 1376
Study 34175006 — intervention group
Group type: COMPARATOR
Intervention: Post-pandemic mental health assessments (8-month follow-up during early stages of the pandemic)
Number of subjects: 1376
Study 34107828 — intervention group
Group type: EXPERIMENTAL
Intervention: One IPL treatment followed by three diode laser treatments
Number of subjects: 45
Study 34107828 — intervention group
Group type: EXPERIMENTAL
Intervention: Two IPL treatments followed by three diode laser treatments
Number of subjects: 45
Study 34107828 — intervention group
Group type: EXPERIMENTAL
Intervention: Three IPL treatments followed by three diode laser treatments
Number of subjects: 45
Study 34107828 — intervention group
Group type: COMPARATOR
Intervention: Diode laser (control group)
Number of subjects: 45
Study 36339420 — intervention group
Group type: EXPERIMENTAL
Intervention: 1, 2, 4, 8, or 12 µg/day CG beta plus rFSH
Number of subjects: 619
Study 36339420 — intervention group
Group type: EXPERIMENTAL
Intervention: CG beta (highest dose group)
Number of subjects: 619
Study 36339420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 619
Study 36339420 — intervention group
Group type: EXPERIMENTAL
Intervention: CG beta
Number of subjects: 619
Study 32374623 — intervention group
Group type: EXPERIMENTAL
Intervention: NUC-1031 (725 mg/m2)/cisplatin (25 mg/m2)
Number of subjects: 828
Study 32374623 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine (1000 mg/m2)/cisplatin (25 mg/m2)
Number of subjects: 828
Study 33417321 — intervention group
Group type: COMPARATOR
Intervention: RAD51 variants G135C and G172T in breast cancer tissue
Number of subjects: 103
Study 33417321 — intervention group
Group type: COMPARATOR
Intervention: RAD51 expression in malignant cells
Number of subjects: 103
Study 33417321 — intervention group
Group type: COMPARATOR
Intervention: G135C and C135C variants
Number of subjects: 103
Study 33417321 — intervention group
Group type: COMPARATOR
Intervention: G172T variant
Number of subjects: 103
Study 33417321 — intervention group
Group type: COMPARATOR
Intervention: G135C and C135C genotypes in triple-negative breast cancer
Number of subjects: 103
Study 32316391 — intervention group
Group type: EXPERIMENTAL
Intervention: High-nucleotide mycoprotein (H-NU)
Number of subjects: 10
Study 32316391 — intervention group
Group type: COMPARATOR
Intervention: Nucleotide-depleted mycoprotein (L-NU)
Number of subjects: 10
Study 32316391 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (H-NU and L-NU)
Number of subjects: 10
Study 33894335 — intervention group
Group type: EXPERIMENTAL
Intervention: pembrolizumab plus pemetrexed–platinum
Number of subjects: 616
Study 33894335 — intervention group
Group type: COMPARATOR
Intervention: placebo plus pemetrexed–platinum
Number of subjects: 616
Study 33069606 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumer co-created infographic about physical activity during a gestational diabetes pregnancy
Number of subjects: 69
Study 33069606 — intervention group
Group type: COMPARATOR
Intervention: Control group (gestational diabetes education alone)
Number of subjects: 69
Study 35972834 — intervention group
Group type: EXPERIMENTAL
Intervention: Cream with glucocorticosteroid and fusidic acid
Number of subjects: 0
Study 35972834 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo cream with fusidic acid
Number of subjects: 0
Study 35972834 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific skin care)
Number of subjects: 0
Study 35972834 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient and Observer Scar Assessment Scale (intervention group)
Number of subjects: 0
Study 35972834 — intervention group
Group type: COMPARATOR
Intervention: Patient and Observer Scar Assessment Scale (control group)
Number of subjects: 0
Study 34062140 — intervention group
Group type: EXPERIMENTAL
Intervention: Voclosporin (23.7 mg twice daily and 39.5 mg twice daily)
Number of subjects: 0
Study 34062140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35296414 — intervention group
Group type: EXPERIMENTAL
Intervention: Online naloxone training
Number of subjects: 220
Study 35296414 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 220
Study 34429089 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application including BSE reminder, training, alarm, and feedback to the therapist, educational movies, and self-assessment.
Number of subjects: 150
Study 34429089 — intervention group
Group type: COMPARATOR
Intervention: Control group (no smartphone application).
Number of subjects: 150
Study 32829109 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT: high-intensity interval training (10× 1 bout: 1 min − 100% Maximal Aerobic Velocity)
Number of subjects: 22
Study 32829109 — intervention group
Group type: EXPERIMENTAL
Intervention: MICT: moderate-intensity continuous training (65% Maximal Aerobic Velocity; kcal equal to HIIT)
Number of subjects: 22
Study 32829109 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HIIT and MICT
Number of subjects: 22